Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255461 | 0.83 | SMN1; SMN2 (0.41) | ALDH1A1HPGDNAMPTLMNA | |
| SCHEMBL181009 | 0.83 | SMN1; SMN2 (0.41) | ALDH1A1HPGDNAMPTLMNA | |
| SCHEMBL2734922 | 0.82 | SMN1; SMN2 (0.39) | ALDH1A1HPGDNAMPTLMNATSHR | |
| SCHEMBL180975 | 0.81 | SMN1; SMN2 (0.45) | ALDH1A1HPGDNAMPTL3MBTL1TSHR | |
| SCHEMBL180930 | 0.80 | TDP1 (0.33) | CNR1CNR2ALDH1A1HPGDLMNA | |
| SCHEMBL2633079 | 0.80 | SMN1; SMN2 (0.36) | CNR1CNR2ALDH1A1HPGDNAMPT | |
| SCHEMBL8663263 | 0.78 | SMN1; SMN2 (0.37) | HPGDLMNATSHRHSD17B10 | |
| SCHEMBL26271158 | 0.77 | HPGD (0.33) | HPGDNAMPTL3MBTL1TSHRHSD17B10 | |
| SCHEMBL28538359 | 0.76 | HDAC1 (0.36) | FOLH1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL15069739 | 0.76 | FOLH1 (0.45) | FOLH1ALDH1A1HPGDLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2410991-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2012-02-01 | — | — | EP | claimed |
| WO-2010111271-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-09-30 | — | — | WO | claimed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | claimed |
| US-11998615-B2 | Functionalized nanoparticles and their use in treating bacterial infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240148882-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | disclosed |
| US-11723982-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230149561-A1 | Functionalized Nanoparticles and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| EP-3386520-B1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | UNIV CALIFORNIA (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20210113655-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-22 | — | — | US | disclosed |
| US-20210113702-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-22 | — | — | US | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040043446-A1 | Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A | NEOSE TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040001892-A1 | Tunable, semi-interpenetrating polymer networks (sIPNS) for medicine and biotechnology | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-01-01 | — | — | US | disclosed |
| WO-2003035830-A2 | EFFICIENT SYNTHESIS OF PROTEIN-OLIGONUCLEOTIDE CONJUGATES | BECKMAN-COULTER, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003031464-A2 | REMODELING AND GLYCOCONJUGATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1218413-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | The Regents of the University of California (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001022922-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-05 | — | — | WO | disclosed |
| US-5965106-A | ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET | PERIMMUNE HOLDINGS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | FOLH1 608/4885CNR1 1065/4885CNR2 1029/4885 |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | FOLH1 1982/4885CNR1 4495/4885CNR2 4529/4885 |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | CSF3R, CSF1R, GMFG | FOLH1 253/4885CNR1 4463/4885CNR2 4545/4885 |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | PTMS, ANPEP, SMURF1 | FOLH1 1214/4885CNR1 4709/4885CNR2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.